好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Racial Disparities in Diabetes Prevalence and Peripheral Neuropathy Characteristics: A Single-center Retrospective Review of Native Hawaiians and Other Pacific Islanders in Hawai‘i
General Neurology
P6 - Poster Session 6 (5:00 PM-6:00 PM)
7-003

To evaluate the burden of diabetes among Native Hawaiian and Other Pacific Islander (NHOPI) patients with peripheral neuropathy in Hawai‘i and to characterize neuropathy features and comorbidities associated with diabetes compared to non-diabetic individuals.

Peripheral neuropathy, a common complication of diabetes, leads to pain, numbness, and sensory loss in the limbs. Native Hawaiians and Other Pacific Islanders (NHOPI) experience disproportionately high rates of diabetes, yet neuropathy patterns across racial groups in Hawai‘i remain understudied.

We performed a retrospective chart review of 375 patients diagnosed with peripheral neuropathy between 2013 and 2025 at a private outpatient neurology clinic. Race and ethnicity were self-reported, and diabetes status was determined using ICD-10 codes and provider documentation. Statistical comparisons were made between diabetic and non-diabetic patients and across racial/ethnic groups.

Diabetes was significantly more common among NHOPI patients (Native Hawaiian: 35.9%; Other Pacific Islander: 57.1%) compared with White (11.3%) and Asian (16.7%) patients (p = 2.77e-05). Diabetic patients exhibited features of both small- and large-fiber neuropathy, including higher rates of pinprick (45.3%), vibration (41.3%), and proprioception (26.7%) loss. They reported fewer torso or back symptoms (8.0% vs. 79.7%) but more frequent metabolic comorbidities, particularly lipid abnormalities (73.3% vs. 42.0%).

These findings demonstrate a disproportionate burden of diabetes-related neuropathy among NHOPI populations and emphasize the need for earlier screening and culturally tailored interventions. Study limitations include the single-clinic design, small subgroup sizes, and a lack of adjustment for demographic and socioeconomic factors.

Authors/Disclosures
Shashi Sharma
PRESENTER
Mr. Sharma has nothing to disclose.
Rae Kamikawa, Student Miss Kamikawa has nothing to disclose.
Orion Goodman Mr. Goodman has nothing to disclose.
Belinda Lim Miss Lim has nothing to disclose.
Jonathan Carino, MSc Mr. Carino has nothing to disclose.
Enrique Carrazana (Neurelis, Inc.) Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences, Apex Labs. Enrique Carrazana has stock in Neurelis, CND, Apex.
Kore K. Liow, MD, FACP (University of Hawaii, John Burns School of Medicine) The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.